tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

ZVRA Stock Latest News

Zevra Therapeutics price target lowered to $22 from $24 at Canaccord
The FlyZevra Therapeutics price target lowered to $22 from $24 at Canaccord
2d ago
ZVRA
Zevra Therapeutics presents data for arimoclomol, OLPRUVA at SSIEM 2024
PremiumThe Fly
Zevra Therapeutics presents data for arimoclomol, OLPRUVA at SSIEM 2024
14d ago
ZVRA
Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium
PremiumPress Releases
Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium
14d ago
ZVRA
Zevra Therapeutics to Participate at Upcoming Investor Conferences
PremiumPress Releases
Zevra Therapeutics to Participate at Upcoming Investor Conferences
22d ago
ZVRA
Zevra Therapeutics reports Q2 EPS (48c), consensus (43c)
PremiumThe Fly
Zevra Therapeutics reports Q2 EPS (48c), consensus (43c)
1M ago
ZVRA
Zevra Therapeutics Inc options imply 8.4% move in share price post-earnings
PremiumThe FlyZevra Therapeutics Inc options imply 8.4% move in share price post-earnings
1M ago
ZVRA
ZVRA Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
ZVRA Earnings this Week: How Will it Perform?
1M ago
ZVRA
Zevra Therapeutics 9.2M share Spot Secondary priced at $6.50
Premium
The Fly
Zevra Therapeutics 9.2M share Spot Secondary priced at $6.50
1M ago
ZVRA
Zevra Therapeutics 9.2M share Spot Secondary priced at $6.50
PremiumThe Fly
Zevra Therapeutics 9.2M share Spot Secondary priced at $6.50
1M ago
ZVRA
Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock
PremiumPress Releases
Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock
1M ago
ZVRA
Zevra Therapeutics announces common stock offering, no amount given
PremiumThe Fly
Zevra Therapeutics announces common stock offering, no amount given
1M ago
ZVRA
Zevra Therapeutics Announces Proposed Public Offering of Common Stock
PremiumPress Releases
Zevra Therapeutics Announces Proposed Public Offering of Common Stock
1M ago
ZVRA
Zevra Therapeutics to Present at Canaccord Genuity’s 44th Annual Growth Conference
PremiumPress ReleasesZevra Therapeutics to Present at Canaccord Genuity’s 44th Annual Growth Conference
1M ago
ZVRA
Zevra Therapeutics price target raised to $18 from $15 at H.C. Wainwright
Premium
The Fly
Zevra Therapeutics price target raised to $18 from $15 at H.C. Wainwright
2M ago
ZVRA
FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C
Premium
Press Releases
FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C
2M ago
ZVRA
FDA Genetic Metabolic Diseases Advisory Committee holds a meeting
PremiumThe Fly
FDA Genetic Metabolic Diseases Advisory Committee holds a meeting
2M ago
ZVRA
Zevra Therapeutics to Report Second Quarter 2024 Financial Results
PremiumPress Releases
Zevra Therapeutics to Report Second Quarter 2024 Financial Results
2M ago
ZVRA
Zevra Therapeutics Announces Key Agreement Updates and Stock Offering
PremiumCompany Announcements
Zevra Therapeutics Announces Key Agreement Updates and Stock Offering
2M ago
8K
ZVRA
Zevra Therapeutics Approaches Key FDA Review and PDUFA Date
PremiumCompany Announcements
Zevra Therapeutics Approaches Key FDA Review and PDUFA Date
2M ago
8K
ZVRA
Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
PremiumPress ReleasesZevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
2M ago
ZVRA
Zevra Therapeutics announces FDA GeMDAC meeting to review arimoclomol
Premium
The Fly
Zevra Therapeutics announces FDA GeMDAC meeting to review arimoclomol
2M ago
ZVRA
Zevra Therapeutics Expands Executive Leadership Team
Premium
Press Releases
Zevra Therapeutics Expands Executive Leadership Team
3M ago
ZVRA

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >